ReviewEuropean respiratory review : an official journal of the European Respiratory Society2012
Pathways in pulmonary arterial hypertension: the future is here.
Review in European respiratory review : an official journal of the European Respiratory Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.
- Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review.BMJ open respiratory research · 2024Pooled it
- Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2015Trial
- Signal Transduction during Metabolic and Inflammatory Reprogramming in Pulmonary Vascular Remodeling.International journal of molecular sciences · 2022Review
- Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study.Frontiers in pharmacology · 2022Article
- β-Arrestin-Mediated Angiotensin II Type 1 Receptor Activation Promotes Pulmonary Vascular Remodeling in Pulmonary Hypertension.JACC. Basic to translational science · 2021Article
- Review
- Single-cell transcriptomic profile of human pulmonary artery endothelial cells in health and pulmonary arterial hypertension.Scientific reports · 2021Article
- Molecular and Genetic Profiling for Precision Medicines in Pulmonary Arterial Hypertension.Cells · 2021Review
- Therapeutic Potential of Regorafenib-A Multikinase Inhibitor in Pulmonary Hypertension.International journal of molecular sciences · 2021Article
- Management of Pulmonary Arterial Hypertension.Current cardiovascular risk reports · 2021Review
- Long noncoding RNAs: emerging roles in pulmonary hypertension.Heart failure reviews · 2020Review
- Current and emerging therapeutic approaches to pulmonary hypertension.Reviews in cardiovascular medicine · 2020Review
- Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway.Pediatric pulmonology · 2019Review
- The Search for Disease-Modifying Therapies in Pulmonary Hypertension.Journal of cardiovascular pharmacology and therapeutics · 2019Review
- Vascular Endothelial Growth Factor Receptor 3 Regulates Endothelial Function Through β-Arrestin 1.Circulation · 2019Article
- Diligustilide releases HInflammopharmacology · 2018Article
- Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats.Frontiers in pharmacology · 2018Article
- Involvement of CaBioscience reports · 2017Article
- Nitric oxide and pulmonary arterial hypertension.Global cardiology science & practice · 2017Review
- Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.Free radical biology & medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
It is well established that the endothelin, nitric oxide and prostacyclin pathways play an important role in the development of pulmonary arterial hypertension (PAH). Indeed, the therapeutic options currently available for the management of PAH all act on one of these mechanistic pathways. However, this is an exciting time for both clinicians and scientists, as increased understanding of the mechanisms involved in the pathogenesis and progression of PAH has resulted in the development of a number of novel therapeutic options. This article highlights how the introduction of new compounds such as macitentan, riociguat and selexipag, which act on the endothelin, nitric oxide and prostacyclin pathways, respectively, have the potential to further improve the prognosis for patients with PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.